Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy: Erratum

Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy: Erratum

Bibliographic Details
Format:	Article
Language:	English
Published:	NLM (Medline) 2022
Online Access:	View Fulltext in Publisher

Similar Items

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy
by: Capdevila, J., et al.
Published: (2022)

Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer
by: Ameya D Puranik, et al.
Published: (2021-07-01)

Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series
by: Matović Milovan
Published: (2012-01-01)

Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors
by: Hasegawa, S., et al.
Published: (2022)

Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
by: Starr JS, et al.
Published: (2020-04-01)

177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
by: Pradeep Thapa, et al.
Published: (2017-01-01)

Radiosynthesis and evaluation of novel acetylcholine receptor radioligands
by: Pimlott, Sally L.
Published: (2004)

Radioligand binding studies on the NMDA receptor in the CNS
by: Sherriffs, Helen J.
Published: (1995)

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
by: Virginia Liberini, et al.
Published: (2020-12-01)

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
by: Baptiste Camus, et al.
Published: (2021-03-01)

Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01)

A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
by: Pashtoon Murtaza Kasi, et al.
Published: (2019-01-01)

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
by: Anna Yordanova, et al.
Published: (2020-11-01)

Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy
by: Judy S. Crabtree
Published: (2017-12-01)

Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand.
by: Mahaveer S Bhojani, et al.
Published: (2011-01-01)

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life
by: Severi S, et al.
Published: (2017-01-01)

Multiple laminin receptors: a radioligand binding approach
by: M. V. Marquezini, et al.
Published: (1991-01-01)

A quarternary radioligand for histamine Hâ†1-receptor
by: Treherne, Jonathan Mark
Published: (1987)

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
by: Fiona Ohlendorf, et al.
Published: (2021-03-01)

Kidney Protection with the Radical Scavenger α<sub>1</sub>-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy
by: Amanda Kristiansson, et al.
Published: (2021-08-01)

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy
by: Abusada, E., et al.
Published: (2022)

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors
by: Ling Wang, et al.
Published: (2013-01-01)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
by: Tiago Nunes da Silva, et al.
Published: (2018-04-01)

Challenges of Caring for an Advanced Chronic Kidney Disease Patient with Severe Thrombocytopenia
by: Tetsu Akimoto, et al.
Published: (2013-11-01)

Challenges of Caring for an Advanced Chronic Kidney Disease Patient with Severe Thrombocytopenia
by: Tetsu Akimoto, et al.
Published: (2013-01-01)

Radionuclide imaging and therapy in patients with neuroendocrine tumors
by: Olga D. Baranova, et al.
Published: (2018-03-01)

Refractory Thrombocytopenia Responds to Octreotide Treatment in a Case of Evans Syndrome with Gastric Neuroendocrine Tumor
by: Kocfa Chung-Delgado, et al.
Published: (2013-01-01)

Refractory Thrombocytopenia Responds to Octreotide Treatment in a Case of Evans Syndrome with Gastric Neuroendocrine Tumor
by: Chung Delgado, Kocfa, et al.
Published: (2014)

mTOR Pathway Expression as Potential Predictive Biomarker in Patients with Advanced Neuroendocrine Tumors Treated with Everolimus
by: Fabio Gelsomino, et al.
Published: (2020-05-01)

Metal-Based PSMA Radioligands
by: Eleni Gourni, et al.
Published: (2017-03-01)

Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands
by: Panagiotis Kanellopoulos, et al.
Published: (2020-06-01)

Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation for an advanced small intestinal neuroendocrine neoplasm: an updated case report
by: Clift Ashley K., et al.
Published: (2017-08-01)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
by: Pamela L Kunz, et al.
Published: (2010-06-01)

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
by: Ralf Schirrmacher, et al.
Published: (2019-01-01)

Radioligand Assay-Based Detection of Antibodies against SARS-CoV-2 in Hospital Workers Treating Patients with Severe COVID-19 in Japan
by: Hidenori Matsunaga, et al.
Published: (2021-02-01)

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
by: Yuheng Hu, et al.
Published: (2021-05-01)

PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose.
by: Geetanjali Arora, et al.
Published: (2012-01-01)

Severe thrombocytopenia due to hypersplenism treated with partial splenic embolisation
by: Hanafiah, M., et al.

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
by: Magdalena Mileva, et al.
Published: (2021-01-01)

Induction of Anti-Tumor Immune Responses by Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in a Murine Model of a Human Neuroendocrine Tumor
by: Michael Bzorek, et al.
Published: (2013-10-01)

Cannot write session to /tmp/vufind_sessions/sess_k3ogduvamu6oe7rdckt37lfagv